Home » Cell Therapeutics Granted Pixantrone Orphan Drug Designation by EMEA for DLBCL
Cell Therapeutics Granted Pixantrone Orphan Drug Designation by EMEA for DLBCL
Monday, Cell Therapeutics Inc. said it has been granted pixantrone orphan drug designation by European Medicines Agency or EMEA for the treatment of [diffuse
large B-cell lymphoma] DLBCL which accounts for around 80% of aggressive non-Hodgkin’s lymphoma.
RTTNews
RTTNews
Upcoming Events
-
07May
-
14May
-
30May